31861-1.fp.png "SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal")
SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
Session evaluation and key learnings
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Ajay Kirtane, EVOLVE SHORT DAPT WEB - Cardiovascular News
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent -
Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
Another Coronary Stent for Patients at High Bleeding Risk∗ | JACC: Cardiovascular Interventions
The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates | tctmd.com
PDF) Evolving Concepts in Post-PCI Antiplatelets Therapy
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
EVOLVE Short DAPT
EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated with a Bioabsorbable Polymer- Ba
Three-month DAPT after PCI with Synergy stent supported in EVOLVE Short DAPT trial - Cardiovascular News
EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case | tctmd.com
EVOLVE Short DAPT Trial Enrollment Complete - Boston Scientific
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives | SpringerLink
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
